Trexquant Investment LP Sells 59,539 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Trexquant Investment LP trimmed its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 50.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 57,364 shares of the company's stock after selling 59,539 shares during the period. Trexquant Investment LP owned approximately 0.12% of Omnicell worth $2,554,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Smartleaf Asset Management LLC increased its stake in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after acquiring an additional 273 shares during the last quarter. Van ECK Associates Corp raised its holdings in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after buying an additional 315 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Omnicell during the 4th quarter worth $53,000. First Horizon Advisors Inc. boosted its stake in Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after buying an additional 355 shares in the last quarter. Finally, KBC Group NV boosted its stake in Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company's stock valued at $92,000 after buying an additional 778 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Omnicell Trading Up 0.4 %

Shares of Omnicell stock traded up $0.11 during midday trading on Friday, reaching $31.19. The company had a trading volume of 566,792 shares, compared to its average volume of 529,211. The stock has a fifty day moving average price of $36.34 and a 200 day moving average price of $41.68. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The firm has a market cap of $1.46 billion, a PE ratio of 115.52, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on OMCL shares. StockNews.com cut shares of Omnicell from a "buy" rating to a "hold" rating in a report on Monday, March 24th. Benchmark reiterated a "buy" rating and set a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Bank of America cut their price objective on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. JPMorgan Chase & Co. lowered their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Finally, Wells Fargo & Company reduced their price target on Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $51.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.